A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

Inclusion criteria: * Signed written informed consent * Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists * Clinically or radiologically documented measurable disease. * Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue * Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG) Exclusion criteria: * Receipt of ADH-1 prior to this clinical study * Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry * History of primary brain tumors or brain metastases * History of spinal cord compression or tumors that have shown any evidence of active bleeding within 30 days before study entry. * Stroke, major surgery, or other major tissue injury within 30 days before study entry * History of congestive heart failure, myocardial infarction, angina, life threatening arrhythmias, significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states